Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA-EP2006 versus Neulasta in healthy volunteers
NL-OMON43539Active, not recruiting
- Sponsor
- Hexal AG
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of pegfilgrastim-bmez and pegfilgrastim in neutropenia (2 arms), sponsored by Hexal AG. Primary endpoints: AUC0-∞ and Cmax. Started Feb 2016; status: active, not recruiting.
02
Drugs
pegfilgrastim-bmezpegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NL-OMON43539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43539.